resisttb
- Dec 1, 2021
- 1 min read

South Africa sets another example of success in beating tuberculosis

During the Union’s 52nd World Conference on Lung Health in late October, Doctors Without Borders (MSF) announced the results of TB-PRACTEAL, the first multi-country randomized controlled clinical trial to report on the efficacy and safety of a multidrug-resistant tuberculosis (MDR-TB) treatment. Time has shown that MDR-TB is a very difficult form of tuberculosis to treat, requiring multidrug therapies to be administered over a period of nine to 24 months. Read Here.

Recent Posts

See All

Public Health Leaders, Researchers, and Activists Launch Campaign to Revolutionize Tuberculosis

The annual World Health Organization (WHO) Global Tuberculosis Report 2022 showed that “the COVID-19 pandemic has reversed years of progress made in the fight to end TB… [In 2021, there were] 1.6 mill

New testing method could make TB diagnosis easier

Tuberculosis can be tough to detect. Diagnosis usually requires coughing up a sputum sample from the lungs, which can be unpleasant, impractical, and even hazardous. But in a promising new study, a mu

Drug-Resistant TB Trial Results Published in New England Journal of Medicine

The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-res